**Harvesting AI for Pathology Diagnostics**

**Avi Veidman, Founder and CEO, Nucleai**

- **Investment Rational**
  Nucleai is an AI healthcare company, in the pathology domain. Nucleai’s platform provides the most comprehensive solution that helps pathologists with their increasing workload, using a machine-based analysis of biopsies. The company’s team includes highly experienced AI experts and leading pathologists. Nucleai is backed up by leading VC funds (Vertex, Grove) and collaborates with leading centers in US and Israel.

- **Business Strategy**
  Nucleai will apply its technology to improve lab efficiency and accuracy by increasing their capacity, hence it will not require new reimbursement codes. The revenues will be made by direct global sales to labs. In the long-term, Nucleai will leverage their unique pathology position that converges many data sources to provide unique insight in precision medicine challenges such as prognosis and prediction.

- **Core Technology**
  Nucleai team has been deploying AI, deep learning, machine vision and big data since 1998, and developed its current technology using access to enormous data source of 25M slides. The team members’ unique experience allows the company to develop advanced solutions and to personalize our AI products based on the common practice, clinical needs and flow of each lab.

- **Product Profile/Pipeline**
  Nucleai’s products cover most biopsies in the pathology lab – GI, prostate and breast, with an additional advanced solution for telepathology. Our products are currently used in the routine flow and clinical studies in various leading centers and labs in US and Israel. The market potential is huge as workload of pathologists is increasing while the number of pathologists is decreasing.

- **What’s Next?**
  We are now developing additional products to continue support our leading position as the most complete solution for pathology labs, while increasing our commercial footprint to additional centers and countries. Our team is growing to support these growth needs. Following our first funding round of $5M, we already received proposals to invest additional funds.